Alligator Bioscience AB (ATORX) - Total Liabilities
Based on the latest financial reports, Alligator Bioscience AB (ATORX) has total liabilities worth Skr103.74 Million SEK (≈ $11.16 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alligator Bioscience AB - Total Liabilities Trend (2005–2025)
This chart illustrates how Alligator Bioscience AB's total liabilities have evolved over time, based on quarterly financial data. See Alligator Bioscience AB working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Alligator Bioscience AB Competitors by Total Liabilities
The table below lists competitors of Alligator Bioscience AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Reliance Chemotex Industries Limited
NSE:RELCHEMQ
|
India | Rs3.39 Billion |
|
Jet Freight Logistics Limited
NSE:JETFREIGHT
|
India | Rs1.05 Billion |
|
Star Combo Pharma Ltd
AU:S66
|
Australia | AU$8.30 Million |
|
Rocky Mountain Chocolate Factory
NASDAQ:RMCF
|
USA | $14.72 Million |
|
Garovaglio y Zorraquin S.A.
BA:GARO
|
Argentina | AR$41.64 Billion |
|
Noble Helium Ltd
AU:NHE
|
Australia | AU$11.07 Million |
|
Irisity AB
ST:IRIS
|
Sweden | Skr121.49 Million |
|
S-Energy Co.Ltd
KQ:095910
|
Korea | ₩161.54 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Alligator Bioscience AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Alligator Bioscience AB worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.80 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 15.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.94 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alligator Bioscience AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alligator Bioscience AB (2005–2025)
The table below shows the annual total liabilities of Alligator Bioscience AB from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr103.74 Million ≈ $11.16 Million |
-55.84% |
| 2024-12-31 | Skr234.93 Million ≈ $25.28 Million |
+120.39% |
| 2023-12-31 | Skr106.59 Million ≈ $11.47 Million |
+32.36% |
| 2022-12-31 | Skr80.53 Million ≈ $8.67 Million |
+58.13% |
| 2021-12-31 | Skr50.93 Million ≈ $5.48 Million |
+38.79% |
| 2020-12-31 | Skr36.69 Million ≈ $3.95 Million |
-30.28% |
| 2019-12-31 | Skr52.63 Million ≈ $5.66 Million |
+32.08% |
| 2018-12-31 | Skr39.85 Million ≈ $4.29 Million |
+58.89% |
| 2017-12-31 | Skr25.08 Million ≈ $2.70 Million |
+1.96% |
| 2016-12-31 | Skr24.59 Million ≈ $2.65 Million |
+27.52% |
| 2015-12-31 | Skr19.29 Million ≈ $2.08 Million |
-34.12% |
| 2014-12-31 | Skr29.27 Million ≈ $3.15 Million |
+221.31% |
| 2011-12-31 | Skr9.11 Million ≈ $980.49K |
+7.85% |
| 2010-12-31 | Skr8.45 Million ≈ $909.14K |
+21.24% |
| 2008-12-31 | Skr6.97 Million ≈ $749.87K |
+8.72% |
| 2007-12-31 | Skr6.41 Million ≈ $689.71K |
+0.39% |
| 2006-12-31 | Skr6.38 Million ≈ $687.02K |
-52.52% |
| 2005-12-31 | Skr13.45 Million ≈ $1.45 Million |
-- |
About Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using N… Read more